Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab vedotin in metastatic solid tumors
NCT04504916Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zilovertamab vedotin in triple-negative breast cancer (TNBC), breast cancer, Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), gastric cancer (GC), pancreatic cancer (PC), sponsored by Merck & Co.. Started Oct 2020; status: terminated.
02
Drugs
zilovertamab vedotin
03
Conditions
triple-negative breast cancer (TNBC)breast cancerNonsquamous Non-Small Cell Lung Cancer (nsNSCLC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04504916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504916.